IP Library Granted Patent US 7,427,601
Granted Patent B2
US 7,427,601 · App. 11/149,181 · Granted Sep 23, 2008

Method for treating tremor

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,427,601
App. No.
11/149,181
Granted
Sep 23, 2008
Kind
B2
Abstract

The present invention is directed to the use of a class of peptide compounds for treating essential tremor and other tremor syndromes.

Claims (16)

1. A method for treating tremor in a subject in need thereof, the method comprising administering to the subject the compound (R)-2-acetamido-N-benzyl-3-methoxypropionamide or a pharmaceutically acceptable salt thereof, wherein the tremor comprises rhythmic oscillatory movement.

2. The method of claim 1 , wherein the tremor is selected from the group consisting of essential tremor, physiologic tremor, enhanced physiologic tremor, undetermined tremor syndrome, primary orthostatic tremor, dystonic tremor, task- and position-specific tremors, parkinsonian tremor syndromes, cerebellar tremor syndromes, Holmes's tremor, palatal tremors, neuropathic tremor syndrome, drug-induced and toxic tremor syndromes, psychogenic tremor, myorhythmia, rest tremor, action tremor, postural tremor, kinetic tremor, isometric tremor and combinations thereof.

3. The method of claim 1 , wherein the compound is administered in a pharmaceutical composition at a dose of the compound of at least 100 mg/day.

4. The method of claim 1 , wherein the compound is administered in a pharmaceutical composition at a dose of the compound not greater than 6 g/day.

5. The method of claim 1 , wherein the compound is administered in a pharmaceutical composition at increasing daily doses until a predetermined daily dose is reached which is maintained during further treatment.

6. The method of claim 1 , wherein the compound is administered in a pharmaceutical composition in no more than three doses per day.

7. The method of claim 1 , wherein the compound is administered in a pharmaceutical composition resulting in a plasma concentration of the compound of 0.1 to 15 μg/ml (trough) and 5 to 18.5 μg/ml (peak), calculated as an average over a plurality of treated subjects.

8. The method of claim 1 , wherein the compound is administered orally or intravenously in a pharmaceutical composition.

9. The method of claim 1 , further comprising administering to the subject a further active agent for the treatment of tremor.

10. The method of claim 9 , wherein the (R)-2-acetamido-N-benzyl-3-methoxypropionamide or salt thereof and the further active agent are administered in a single dose form or separate dose forms comprising a first composition comprising the (R)-2-acetamido-N-benzyl-3-methoxypropionamide or salt thereof and a second composition comprising the further active agent.

11. The method of claim 1 wherein the subject is a mammal.

12. The method of claim 11 wherein the subject is a human.

13. A pharmaceutical composition comprising

(a) (R)-2-acetamido-N-benzyl-3-methoxypropionamide or a pharmaceutically acceptable salt thereof, and

(b) a further active agent for the treatment of tremor.

14. The pharmaceutical composition according to claim 13 which is a single dose form or comprises separate dose forms comprising a first composition comprising the compound (a), and a second composition comprising the further active agent (b).

Assignments (3)
CORRECTIVE CHANGE OF NAME Recorded Apr 13, 2011
From: SCHWARZ PHARMA AG
To: UCB PHARMA GMBH
Reel/Frame 026132/0268 →
CHANGE OF NAME Recorded Feb 26, 2010
From: SCHWARZ PHARMA AG
To: UCB PHARMA GMBH
Reel/Frame 023985/0822 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 10, 2005
From: STOEHR, THOMAS
To: SCHWARZ PHARMA AG
Reel/Frame 016687/0917 →